Compare AGIG & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGIG | PLRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 63.2M |
| IPO Year | 2025 | 2020 |
| Metric | AGIG | PLRX |
|---|---|---|
| Price | $0.92 | $0.99 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 117.4K | ★ 373.1K |
| Earning Date | 11-18-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $410,632.00 | N/A |
| Revenue This Year | $1,896.92 | N/A |
| Revenue Next Year | $21.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $0.97 |
| 52 Week High | $5.31 | $1.95 |
| Indicator | AGIG | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 34.84 |
| Support Level | $0.86 | N/A |
| Resistance Level | $1.10 | $1.37 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 6.64 | 11.39 |
Abundia Global Impact Group Inc. is a technology solutions company operating in recycling, renewable energy, environmental change, fuels, and chemicals sectors, mainly focused on low-carbon energy solutions. The company uses waste plastics and biomass to produce crude or drop-in alternatives to fossil-derived energy, fuels, and chemicals through proprietary, licensed, and commercialized technologies, forming a complete process. It operates through its subsidiary and integrates feedstocks, technology, and off-take partners into a complete commercial chain. Its segments include Oil and Gas (O&G), which generates maximum revenue, and Renewables, which consists of its low-carbon fuels and renewable chemicals business.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.